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Abstract
Background: Clinical, immunologic and virologic outcomes at large HIV/AIDS care clinics in
resource poor settings are poorly described beyond the first year of highly active antiretroviral
treatment (HAART). We aimed to prospectively evaluate long-term treatment outcomes at a large
scale HIV/AIDS care clinic in South Africa.
Methods: Cohort study of patients initiating HAART between April 1, 2004 and March 13, 2007,
and followed up until April 1, 2008 at a public HIV/AIDS care clinic in Johannesburg, South Africa.
We performed time to event analysis on key treatment outcomes and program impact parameters
including mortality, retention in care, CD4 count gain, virologic success and first line regimen
durability.
Results: 7583 HIV-infected patients initiated care and contributed to 161,000 person months
follow up. Overall mortality rate was low (2.9 deaths per 100 person years, 95% CI 2.6-3.2), but
high in the first three months of HAART (8.4 per 100 person years, 95% CI 7.2-9.9). Long-term
on-site retention in care was relatively high (74.4% at 4 years, 95%CI 73.2-75.6). CD4 count was
above 200 cells/mm3 after 6 months of treatment in almost all patients. By the fourth year of
HAART, the majority (59.6%, 95%CI 57.8-61.4) of patients had at least one first line drug (mainly
stavudine) substituted. Women were twice as likely to experience drug substitution (OR 1.97, 95%
CI 1.80-2.16). By 6 months of HAART, 90.8% suppressed virus below 400 copies. Among those
with initial viral suppression, 9.4% (95% CI 8.5-10.3%) had viral rebound within one year of viral
suppression, 16.8% (95% CI 15.5-18.1) within 2 years, and 20.6% (95% CI 18.9-22.4) within 3 years
of initial suppression. Only 10% of women and 13% of men initiated second line HAART.
Conclusion: Despite advanced disease presentation and a very large-scale program, high quality
care was achieved as indicated by good long-term clinical, immunologic and virologic outcomes and
a low rate of second line HAART initiation. High rates of single drug substitution suggest that the
public health approach to HAART could be further improved by the use of a more durable first line
regimen.
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Background
Infection with human immunodeficiency virus (HIV)
affects over 33 million people globally[1]. Global access
to highly active antiretroviral therapy (HAART) has
increased dramatically, but the majority of those in need
remain untreated, especially in sub-Saharan Africa. With
more than five million individuals living with HIV and
AIDS, South Africa has the largest population of HIV-
infected individuals[1,2]. Following the political commit-
ment made to include HAART in the Comprehensive
Care, Management and Treatment program of the public
health sector from April 2004 onwards, South Africa now
has the largest number of people receiving HAART in the
world[3]. Scale-up of HAART has however been slower
than anticipated, and the treatment gap remains in excess
of 500,000 individuals.
Antiretroviral treatment roll-out clinics in sub-Saharan
Africa have achieved clinical, immunologic and virologic
outcomes in the first year of HAART comparable to those
observed in developed countries [4-14]. Little is known
about the longer term outcomes of these large-scale roll-
outs. A recent review of ART programs in sub-Saharan
Africa suggested that, due to loss to follow up and death,
only 60% of those initiating HAART are still on treatment
by the end of year two[15]. There is thus legitimate con-
cern that a focus on numbers of people initiated on
HAART may compromise quality of care.
In this study of a large (> 7,500 patients) and rapidly
expanding (> 200 new patients each month since 2004)
clinic in Johannesburg, South Africa, we evaluated the
outcomes of the first four years of activity (> 160,000 per-
son months follow-up) of a South African Department of
Health program by comprehensively assessing five key
parameters: mortality, loss to follow-up, CD4 count gain
viral suppression, and durability of first line HAART regi-
men.
Methods
Study site and inclusion criteria
The Themba Lethu Clinical Cohort is a prospective clini-
cal cohort of adults initiating HAART in Johannesburg,
South Africa. The program is funded by the South African
National and Gauteng Department of Health, with sup-
port from Right to Care funded by USAID and PEPFAR.
The Themba Lethu Clinic at the regional Helen Joseph
Hospital in urban Johannesburg has over 17,000 patients
in care and is currently the largest single clinic providing
HAART in South Africa, and one of the largest HAART
clinics worldwide.
Patients were included in this study if they initiated
HAART between 1 April 2004 and 31 March 2007.
Patients were censored at death, loss to follow-up or on 31
March 2008, whichever came first.
Routine HIV care, treatment and data collection
Patients are referred to the clinic from voluntary coun-
seling and testing clinics, hospitals, prenatal care facilities,
other ART clinics or by self-referral. HAART-eligible
patients attend educational and adherence sessions, and
are assessed by a physician prior to initiating treatment.
After HAART initiation, patients are scheduled for
monthly pharmacy visits, clinical visits at month 4 and
every 6 months thereafter, and additional visits whenever
needed. Patients receive all antiretroviral medications free
of charge but were required to pay 35 Rand (about $5 US)
per clinic visit prior to October 2006, after which all fees
were eliminated. Patients more than three months late for
a scheduled clinic or pharmacy visit are actively traced
(three phone calls and a home visit if needed) to ascertain
the reason for loss to follow-up.
As per the South African national guidelines, the majority
of patients receive a first-line HAART regimen of stavudine
(d4T), lamivudine (3TC), and either efavirenz (EFV) or
nevirapine (NVP). Most pregnant women receive lopina-
vir boosted with ritanovir (LPVr) in place of EFV or NVP.
Second-line HAART consists of AZT, didanosine (DDI),
and LPVr.
Clinical and laboratory (including CD4 count, viral load
and hemoglobin) data are collected at all scheduled visits,
except for viral load which is not collected at baseline. All
data were stored in the TherapyEdge-HIV™ (Associated
Biological Systems - SA) database, and analyzed in SAS
v9.1.3 (SAS Institute, NC, USA).
Data quality
Results were regularly controlled for quality by a senior
nurse or data quality assurance manager. Duplicate entry
of CD4 counts, viral loads, and hemoglobin from the
National Health Laboratory Service database into the
TherapyEdge-HIV database demonstrated high quality of
data entry as 98.8% of values matched between the two
databases.
Definitions
Patients more than three months late for a scheduled visit,
and on whom the tracing team was unable to gain infor-
mation were categorized as lost to follow-up. Retention into
care refers to patients known to be alive and receiving
HAART at Themba Lethu Clinic at the end of follow up
(March 31, 2008). Viral suppression was defined as
achieving viral load below 400 copies per ml. Initial viro-
logic success was defined as achieving a viral suppression
within six months of HAART initiation in patients with a
viral load measured between 30 days and 6 months of
HAART. Viral rebound was defined as two consecutive (or
one if no additional measurement was available) viral
load measurements greater than 400 copies/ml, or one
viral load greater than 5000 following initial virologic suc-Journal of the International AIDS Society 2009, 12:38 http://www.jiasociety.org/content/12/1/38
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cess. Body mass index (BMI) was measured in kg/m2 and
categorized as underweight (BMI < 18.5), normal (18.5 ≤
BMI < 25), overweight (25 ≤ BMI < 30), and obese (BMI ≥
30) [16]. Anemia was defined as a hemoglobin (Hb) value
below 13.0 g/dl (men), 12.0 g/dl (women), or 11.0 g/dl
(pregnant women)[17], Hb values were down-adjusted by
0.65 g/dl because of altitude[18]. Baseline covariates were
those collected closest to time of initiation of HAART, and
no more than four months before initiation of HAART or
one month after initiation.
Statistical analysis
Baseline demographics were characterized using standard
descriptive statistics. Missing baseline height (n = 48) or
weight (n = 20) was assigned using median height and
weight by gender. Chi-square tests were used to compare
categorical variables and Wilcoxon rank-sum tests for con-
tinuous variables by category. Rates were estimated using
crude Poisson models.
To examine the effect of CD4 count on mortality and loss
to follow-up, we created Kaplan-Meier curves stratified by
baseline CD4 counts, and used competing-risks Cox pro-
portional hazards models [19,20] to estimate the effect of
CD4 count on both death and loss to follow-up simulta-
neously. In addition, we used inverse probability of cen-
soring weights to adjust estimates of mortality for loss to
follow-up using measured covariates [21].
CD4 gain was assessed using two linear generalized esti-
mating equations models with an unstructured correla-
tion matrix. To allow the slope of CD4 increase to change
over time, the first model included the main variable of
months since HAART initiation, indicator variables for
baseline CD4 count, and static changepoints at months 4,
10, and every 6 months thereafter (corresponding to rou-
tine clinic visits) until end of follow-up. To allow the
slope to change both in time and by initial CD4 count, the
second model included all terms from the first model as
well as interaction terms between baseline CD4 count cat-
egories, continuous time and all static changepoints.
Time to drug substitution, initiation of second-line
HAART or virologic failure was evaluated using Kaplan-
Meier curves with right censoring of the latter at time of
last viral load assessment and censoring at time of death
and loss of follow up. Rates of changes in drug regimens
and drug toxicities were assessed using Poisson models
and simple descriptive statistics.
All analyses were intent-to-treat with regards to HAART,
ignoring treatment interruptions. Time to loss to-follow-
up was set at the last observed visit plus half the mean
time between clinic visits of any kind while in care (20
days). Where CD4 counts or viral load measurements
were missing, complete case analysis was performed. Mul-
tiple imputation (10 imputations) for missing CD4
counts was performed to check the assumption that com-
plete case analysis was appropriate.
This study was reviewed by the Institutional Review
Boards of the University of the Witwatersrand and the
University of North Carolina at Chapel Hill.
Results
Baseline characteristics
Between 1 April 2004 and 31 March 2007, a total of 7583
(about 210 new patients each month) initiated first-line
HAART at the clinic. Data from 7536 (99.4%) patients
was available for analysis (Table 1). Forty patients were
excluded due to missing demographic information and
seven because of errors in recorded dates of therapy. The
majority (83.8%) of non-pregnant patients initiated d4T-
3TC-EFV, 7.9% initiated d4T-3TC-NVP, 2.0% initiated
d4T-3TC-LPV/r, and 6.3% initiated other regimens. In
contrast, most pregnant women (84.0%) initiated d4T-
3TC-LPVr. Two-thirds (66.5%) of patients were women of
whom 11.5% were pregnant at time of HAART initiation.
Mean age was 35.4 years in women and 38.7 years in men
(p < 0.0001) (Table 1). At time of ART initiation, more
than half (56%) of patients were unemployed.
Patients presented with advanced HIV disease, with
median baseline CD4 count of 87 cells/mm3 (IQR 31-
158), one third (34.4%) of patients initiated HAART at
CD4 < 50 cells/mm3, and19.1% of patients were under-
weight. Men presented at an older age and with more
advanced disease (lower CD4 counts, lower BMI, anemia
and WHO III and IV disease) compared to non-pregnant
women, and non-pregnant women presented with more
advanced disease compared to pregnant women.
Survival, loss to follow-up and retention in care
During 161,000 person-months of follow-up (mean 21.4
months, median 20.3 months), 385 (5.1%) patients died
and 1234 (16.4%) patients were lost to follow up. More
than one in three deaths (39.2%, n = 151) and losses to
follow-up (38.9%, n = 480) occurred in the first 90 days
of treatment. The crude rate of death was 2.9 deaths per
100 person-years (95% CI 2.6-3.2) overall. Early death
rate was higher: 8.4 (95% CI 7.2-9.9) per 100 person-
years in the first three months and 6.8 (95% CI 6.0-7.7)
per 100 person-years in first six months of HAART.
Crude survival curves for death and loss to follow-up are
shown in Figures 1 and 2. In a competing risks analysis,
risk of death was almost five times higher (HR 4.87, 95%
CI 2.94-8.09) among patients with baseline CD4 count ≤
50 cells/mm3 compared to those with baseline CD4 count
above 200 cells/mm3. In contrast, baseline CD4 was onlyJournal of the International AIDS Society 2009, 12:38 http://www.jiasociety.org/content/12/1/38
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a weak predictor of loss to follow up (CD4 ≤ 50 cells/mm3
compared to CD4 > 200 cells/mm3, HR 1.18, 95% CI
0.96-1.43). Inverse probability of censoring weighted esti-
mates of the effect of CD4 count on mortality produced
qualitatively very similar results. Multiple imputation
analyses indicated that a complete case analysis did not
affect the estimated effect of CD4 count on hazard of
death during follow-up.
The Kaplan-Meier estimates of retention into care were
82.8% (95% CI 81.9-83.6) at 1 year, 77.5% (76.5-78.5) at
2 years, 75.2% (74.1-76.3) at 3 years and 74.4% (73.2-
75.6) at 4 years. This corresponds to monthly attrition
rates of 1.43 per month in the first 12 months of HAART,
0.94 per month in the first two years, 0.69 per month in
the first three years, and 0.53 in the first four years of
HAART.
CD4 response
A first follow up CD4 count was available for 5601
(74.3%) patients after approximately 4 months (median
118 days, IQR 111-139 days, range 47-198 days). The
observed median and mean CD4 count at four months of
treatment was 206 and 227 cells/mm3. The observed
Table 1: Baseline characteristics of 7536 individuals enrolled in Themba Lethu Clinical Cohort (TLCC) by gender and pregnancy 
status
Female,
pregnant
(n = 574)
Female,
non-pregnant
(n = 4437)
Male
(n = 2525)
p value
(non-pregnant female vs. male)
Age (Median and IQR) 34.0
(29.4-40.2)
34.9
(30.1-41.2)
37.2
(32.8-43.3)
< 0.0001 †
Ethnicity 0.5818
African or black 560 (97.6) 4253 (95.9) 2375 (94.1)
Coloured 14 (2.4) 153 (3.5) 97 (3.8)
Asian, White, or Missing 0 (0.0) 31 (0.7) 53 (2.1)
Employment < 0.0001
Employed, student, retired 195 (34.0) 1455 (32.8) 1086 (43.0)
Unemployed 354 (61.7) 2619 (59.0) 1262 (50.0)
Unknown or missing 25 (4.4) 363 (8.2) 177 (7.0)
BMI < 0.0001
< 18.5 7 (1.2) 786 (17.7) 639 (25.3)
18.5-24.9 208 (36.2) 2369 (53.4) 1538 (60.9)
25-29.9 230 (40.1) 829 (18.7) 279 (11.1)
≥ 30 128 (22.3) 421 (9.5) 54 (2.1)
Missing 1 (0.2) 32 (0.7) 15 (0.6)
Hemoglobin* 0.7088
Normal 399 (69.5) 2095 (47.2) 1202 (47.6)
Low 163 (28.4) 2298 (51.8) 1294 (51.3)
Missing 12 (2.1) 44 (1.0) 29 (1.2)
WHO stage 0.0003
I 427 (74.4) 1944 (43.8) 1011 (40.0)
II 64 (11.2) 566 (12.8) 286 (11.3)
III 74 (12.9) 1482 (33.4) 927 (36.7)
IV 9 (1.6) 445 (10.0) 301 (11.9)
CD4 count
Median (IQR) 146 (91-192) 86 (32-157) 75 (23-146) < 0.0025 †
Mean (95% CI) 145 (138-152) 111 (107-114) 98 (94-102) < 0.0001 ‡
≤ 50 53 (9.2) 1370 (30.9) 950 (37.6) < 0.0001
51-99 91 (15.9) 885 (20.0) 453 (17.9)
100 - 199 249 (43.4) 1319 (29.7) 703 (27.8)
200 - 349 91 (15.9) 366 (8.3) 169 (6.7)
≥ 350 6 (1.1) 129 (2.9) 61 (2.4)
Missing 84 (14.6) 368 (8.3) 189 (7.5)
Initial HAART regimen < 0.0001
d4T-3TC-EFV 54 (9.4) 3622 (81.6) 2211 (87.6)
d4T-3TC-NVP 33 (5.8) 436 (9.8) 117 (4.6)
d4T-3TC-LPVr 482 (84.0) 112 (2.5) 24 (1.0)
Other 5 (0.9) 267 (6.0) 173 (6.9)
All figures are expressed as number (% total), except where noted. P-values are two-sided by chi-square test of general association across all 
categories by sex, except † Wilcoxon rank-sum test or ‡ t-test. *Lower limit of normal hemoglobin is 12.35 g/dl for men; 11.35 g/dl for non-
pregnant women; and 10.35 g/dl for pregnant women.Journal of the International AIDS Society 2009, 12:38 http://www.jiasociety.org/content/12/1/38
Page 5 of 11
(page number not for citation purposes)
mean four-month CD4 gain was 117 cells/mm3 and dif-
fered by baseline CD4 count: 71 CD4 cells/mm3 for indi-
viduals with a baseline CD4 > 200 cells/mm3 compared to
122 CD4 cells/mm3 for those with baseline CD4 ≤ 200
cells/mm3 (p < 0.0001). The estimated mean CD4 count
during the first three years of HAART by baseline CD4
count is shown in Table 2. CD4 count continued to rise at
each time point, although at a slower rate after the first six
months of HAART.
Viral suppression and viral rebound
Among individuals who had viral load measured between
30 days and six months after HAART initiation (n = 5263
or 69.8%), 90.8% suppressed virus to ≤ 400 copies/ml.
Probability of initial viral suppression did not differ by
baseline CD4 count. Of the 485 patients who failed to
achieve initial virologic success, 294 (60.6%) achieved
viral suppression during follow-up of which about half (n
= 144 or 49%)) suppressed on their first line HAART reg-
imen.
Among those with initial virologic success, the Kaplan-
Meier estimate of the proportion of patients with docu-
mented viral rebound was 9.4% (95% CI 8.5-10.3%)
within one year of initial suppression, 16.8% (95% CI
15.5-18.2) within 2 years, and 20.6% (95% CI 18.9-22.4)
within 3 years of initial suppression (Figure 3). Using a
more conservative viral rebound definition of two viral
loads > 400 copies per ml or one viral load > 5000 ml, the
estimated proportion of patients with viral rebound at 3
years was 16.5% (95%CI 15.9-18.2). Only 10% of women
and 13% of men initiated second line HAART.
Durability of first line regimen
A Kaplan-Meier curve of time to first drug substitution
(excluding switch to second-line drug regimens) by gen-
der is illustrated in Figure 4, and by individual drug in Fig-
ure 5. Overall, an estimated 59.6% (95%CI 57.8-61.4) of
patients had experienced one or more drug substitutions
by the end of four years HAART. The rate of first drug sub-
stitution in this cohort was 29.1 (95% CI 28.0-30.2) per
100 person-years. Women were twice as likely as men to
experience such a drug substitution (HR 2.19, 95% CI
2.00-2.39). This association was not only due to drug sub-
stitutions due to pregnancy (excluding pregnant women,
crude HR for female gender 1.97, 95% CI 1.80-2.16). The
Kaplan-Meier curves of survival by CD4 count by time since HAART initiation Figure 1
Kaplan-Meier curves of survival by CD4 count by time since HAART initiation. Note that the scale of the y-axis 
starts at 0.75 for readability.Journal of the International AIDS Society 2009, 12:38 http://www.jiasociety.org/content/12/1/38
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most common substitution was from d4T-3TC-EFV to
AZT-3TC-EFV (38% of first drug-regimen changes).
Peripheral neuropathy, lactic acidosis or symptomatic
hyperlactatemia, and lipodystrophy were the most fre-
quent toxicities with incidence rates of 8.7 cases per 100
person-years of follow-up (95% CI 8.1-9.2) for peripheral
neuropathy, 5.1 (95% CI 4.7-5.5) per 100 person-years
for lactic acidosis or symptomatic hyperlactatemia, and
4.9 (4.5-5.3) cases per 100 person-years for lipodystro-
phy. Compared to men, women experienced peripheral
neuropathy at a lower rate (HR 0.83, 95% CI 0.73-0.95),
but lipodystrophy and lactic acidosis or symptomatic
hyperlactatemia at higher rates than men (HR = 5.82, 95%
CI 4.35-7.79 and HR = 2.68, 95% CI 2.17-3.31, respec-
tively).
Kaplan-Meier curves of lost to follow-up by CD4 count by time since HAART initiation Figure 2
Kaplan-Meier curves of lost to follow-up by CD4 count by time since HAART initiation. Patients were categorized 
as lost to follow-up if more than three months late for a scheduled visit, and if the tracing team was unable to gain information. 
Note that the scale of the y-axis starts at 0.75 for readability.
Table 2: Estimated* absolute CD4 count during first 3 years of HAART at HIV/AIDS clinic in Johannesburg, South Africa
Months post HAART initiation
036 1 2 1 8 2 43 6
Overall (n = 7536) 111 (1) 196 (2) 239 (2) 289 (2) 341 (2) 372 (3) 441 (4)
Baseline CD4 category
CD4 ≤ 50 (n = 2372) 23 (1) 116 (2) 167 (2) 229 (3) 284 (4) 330 (5) 349 (5)
50 < CD4 ≤ 100 (n = 1429) 77 (1) 171 (2) 214 (3) 255 (4) 298 (5) 330 (6) 377 (10)
100 < CD4 ≤ 200 (n = 2271) 150 (1) 242 (2) 284 (3) 322 (3) 367 (4) 402 (5) 428 (10)
CD4 > 200 (n = 822) 317 (6) 362 (6) 392 (6) 434 (7) 470 (8) 506 (9) 548 (20)
*Mean (standard deviation) CD4 counts were estimated by linear generalized estimating equations model using CD4 count data on patients alive 
and in careJournal of the International AIDS Society 2009, 12:38 http://www.jiasociety.org/content/12/1/38
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Second-line HAART (AZT-DDI-LPVr) was initiated by 420
individuals after a median time of 507 (IQR 309-721)
days. The crude rate of initiation of second-line therapy
was 3.2 (95% CI 2.9-3.6) per 100 person-years. Women
were less likely to initiate second-line HAART than men
(HR = 0.81, 95% CI 0.66-0.99). The proportion of
patients initiating second-line HAART within the first four
years of HAART was 10% for female patients and 13% for
male patients (Figure 6). Second-line HAART was initiated
in 81% (342 of 420) following two consecutive viral load
measurements above 400 copies/ml, in 6% (27 of 420)
following one viral load measurement above 400 copies/
ml, and in 12% (51 of 420) on clinical or immunologic
grounds, without documented loss of viral suppression.
Discussion
Our experience demonstrates that rapid scale-up of
HAART using a public health approach in sub-Saharan
Africa, essential to confronting the HIV/AIDS epidemic,
can be accompanied by high quality care. The analysis of
7536 patients initiating HAART in the first four years
activity of a busy urban South African ART clinic demon-
strated good long-term clinical, immunologic and viro-
logic outcomes, good retention into care, but poor
durability of the first line regimen due to high rates of tox-
icity. Our results thus provide a robust assessment of ART
clinic outcomes beyond those previously reported from
sub-Saharan African, which demonstrated short term suc-
cess (median follow-up 12 months or less) at smaller roll-
out clinics (which typically enroll 50-60 new patients per
clinic per month) [5,6,8-14,22].
We observed a low overall mortality, with a crude overall
death rate of 2.9 deaths per 100 person years, comparable
to that observed in the Swiss HIV cohort study [23], but a
relatively high death rate of 8.4 per 100 person years in the
first 90 days of HAART. The overall and early death rate
was comparable to that reported from two other South
African clinics[22], but lower compared to those reported
from other large African ART clinics, even though the level
of immunosuppression in our patient population
(median baseline CD4 count 87 cells/mm3 and 34.4% of
patients CD4 count below 50 cells/mm3) was similar. For
example, the death rate observed in a clinic-based ART in
Lusaka, Zambia was 16.1 per 100 person years overall,
and 26 per 100 person years and in the first 90 days of
HAART [13]. The mortality rates in a home-based care
program in Uganda was 5 per 100 person years overall
and 14 per 100 person years in the first 110 days of
HAART [24]. The low mortality rates observed in our
cohort may, in part, be due to access to tertiary care level
diagnostics and hospital care. Another possibility is that
some of those lost to follow-up might have died. How-
ever, the proportion of patients with a last documented
Kaplan-Meier estimates of viral rebound among patients with initial viral suppression Figure 3
Kaplan-Meier estimates of viral rebound among patients with initial viral suppression. Initial virologic success is 
defined as viral load ≤ 400 copies/ml within six months of HAART initiation. Viral rebound is defined as two consecutive (or one 
if no additional measurement was available) viral load measurements greater than 400 copies/ml, or one viral load greater than 
5000 among patients with initial virologic success.Journal of the International AIDS Society 2009, 12:38 http://www.jiasociety.org/content/12/1/38
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CD4 count below 50 cells/mm3 was twice as high (50%
vs 25.7%) among those who died compared to those lost
to follow up. Even with a CD4 count of 50 cells/mm3 or
less, absolute risk of death was very small among patients
in care at the Themba Lethu Clinic, with only 120 deaths
among 11,436 person-months in which such a CD4 count
was observed. As a result, mortality rates did not change
when accounting for loss to follow-up using inverse prob-
ability of censoring weights [21].
The four-year 74.4% retention into care was high com-
pared to the rather pessimistic two-year 60% retention
estimate in a recent systematic review of African ART clin-
ics by Rosen et al [15]. The discrepancy may be due to the
short (9.9 months weighted average) follow up of the
studies included in the systematic review. In our popula-
tion, monthly attrition rates dropped from 1.43 in the first
twelve months to 0.53 in the first four years of clinic activ-
ity. Estimating retention rates based on short term follow
up may thus substantially underestimate retention into
care.
We observed good virologic responses to treatment and
relatively infrequent first line treatment failure. By month
6 of HAART, 90.8% of patients achieved viral suppression.
Viral rebound within the first 3 years of achieving suppres-
sion (corresponding to approximately the first 3.5 years of
HAART) was observed in an estimated 20.6% of patients
experiencing viral rebound, which is slightly lower than
the 27% estimate of viral rebound observed within the
same time period in treatment naïve patients in the EuroS-
IDA study [25]. An estimated 11% of patients switched to
a second line regimen within four years of treatment. The
observed rate of switching to second-line drug regimen
was 3.2 per 100 person-year, substantially lower than the
13 per 100 person years clinical failure rate reported from
Zambia [13], even when we analyzed data for a four-year
follow-up period compared to the one-year follow-up
period in Zambia. This lower switch rate in our cohort and
the observation that 87% switched to second line regimen
after documented virologic failure suggest that access to
viral load measurements may actually reduce the rate of
switching to a second line regimen.
Despite good clinical, immunologic and virologic out-
comes, the durability of the first line regimen in this pop-
ulation was poor, with an estimated 59.6% of patients
experiencing at least one drug substitution in their first
line regimen (mostly d4T) in the first four years of treat-
ment. This observation is especially alarming taken into
Kaplan Meier estimates of time to first change of any kind to initial HAART regimen, separated by gender Male or Female Figure 4
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account the public health approach, where a limited
number of standardized HAART regimens are available, in
contrast to the more than 20 antiretroviral drugs in indus-
trialized countries. Female patients were twice as likely to
experience drug substitutions, in part due to the higher
rates of some drug toxicities and to a lesser extent to
switching of antiretroviral drugs for reasons of pregnancy.
These estimates for first line substitution are higher than
those reported in another South African cohort, where
only 28% of patients experienced substitution of at least
one drug in the first 3 years of treatment [26]. The reason
for this important difference is unclear. In Zambia, substi-
tution rates in the first year of treatment were 13, 27.1 and
12 per 100 person years for d4T, AZT and NVP, respec-
tively, which corresponds closer to the overall drug substi-
tution rate of 29 per 100 person years overall observed in
our cohort.
Our analysis has many strengths including a large sample
size, resulting in robust estimates, the prospective stand-
ardized data collection, and the use of time-to-event anal-
ysis instead of cross sectional assessment, thus
overcoming the limitation of overrepresentation of
patients with short follow-up. Our analysis also has a
number of limitations, chiefly related to the observational
nature of the cohort, missing data (especially viral load
measurements at baseline and in 30% of patients at fol-
low up) and use of routine data collected from a high
workload clinic. Some deaths may have been misclassi-
fied as loss to follow-up, despite the implementation of
active contact tracing of patients [27]. The observation
that low CD4 count was a risk factor for death but not loss
to follow up suggests that the magnitude of this bias is
small. The reasons for the high rates of loss to follow-up
are unclear but may be related to the poor socio-economic
status and high mobility of the population. Generalizabil-
ity of results may be limited because of the use of data
from a single clinic located at a tertiary care hospital, the
dominant use of EFZ-containing first line regimens, access
to viral load measurements, and the higher access to
resources, both human and financial, as compared to
many other sub-Saharan African settings.
Conclusions
In this large patient cohort in Johannesburg, South Africa,
we observed good long-term retention and excellent clin-
ical, immunologic and virologic outcomes. The relatively
high early mortality rate and high loss to follow up in the
first months of treatment presented an important chal-
lenge to achieving the best possible HAART outcomes,
and suggests the need to strengthen strategies that pro-
mote early HIV diagnosis, early access to care, and rapid
Kaplan Meier estimates of first line regimen substitutions during first 4 years of HAART Figure 5
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initiation of HAART in the very ill patients. The high rate
of single drug substitution in this population strongly sug-
gest that the formulation of an easy-to-use, non-toxic and
more durable first line regimen will be fundamental in the
success of the public health approach to antiretroviral
treatment in resource poor settings.
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